Search Results for Fibrosis

As the COVID-19 continues to pose extreme challenges to healthcare systems, it is becoming impossible to avoid the overlap between COVID-19 and NASH pandemics. Numerous trials are being conducted despite the crisis and the COVID-19 pandemic has disrupted many aspects of NASH clinical trials, such as patient recruitment, administration...

Non-alcoholic fatty liver disease (NAFLD) has become the most frequently encountered chronic liver disease and is an increasingly important cause of liver cirrhosis as well as other adverse events. The authors of this article retrospectively developed and validated a model to predict hepatic decompensation in NAFLD patients with cirrhosis and compared...

Statins and NAFLD/NASH, a lipid-related pathology present a complex relationship. As a matter of fact, some statins are known to be hepatotoxic, even though it seems clinically significant hepatic injury caused by lipid-lowering medications remains rare. A question can be asked: is it possible that statins...

Non-alcoholic steatohepatitis (NASH) leads to cirrhosis and is associated with a substantial socioeconomic burden, which, coupled with rising prevalence, is a growing public health challenge. Nevertheless, there has been little research into the socioeconomic burden associated with NASH....

Our current understanding of the natural history of NAFLD is incomplete due to a limited knowledge of patient and clinical factors in addition to fibrosis stages that are associated with progression to advanced liver diseases and death. Thus, the aims of the analysis by Ali Canbay et al. (Department of Internal Medicine, Ruhr-University, Bochum, Germany) were...

The goal of K. Cusi et al. (Division of Endocrinology, Diabetes and Metabolism, University of Florida, USA) was to review evidence about the complex association between NAFLD and T2DM, and highlight the potential for disease co-management with the available...

NAFLD comprises a spectrum of progressive liver pathologies, ranging from simple steatosis to NASH, fibrosis, and cirrhosis. A liver biopsy is currently required to stratify high‐risk patients. Predicting the degree of liver inflammation and fibrosis using non‐invasive tests remains challenging...